# A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

> **NCT07227636** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 284 (estimated)

## Conditions studied

- Colorectal Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Botensilimab
- **DRUG:** Balstilimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07227636
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2030-11
- **Final completion:** 2030-11
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227636, "A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07227636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*